ArticleF&S reports2026

Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.

Peng-Hui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.